Copyright
©The Author(s) 2015.
World J Gastroenterol. May 21, 2015; 21(19): 6044-6051
Published online May 21, 2015. doi: 10.3748/wjg.v21.i19.6044
Published online May 21, 2015. doi: 10.3748/wjg.v21.i19.6044
Table 2 Heterogeneity analysis of the biological agents compared to placebo (%)
| Response | Remission | Mucosal healing | Serious adverse events | ||||
| Induction | Maintenance | Induction | Maintenance | Induction | Maintenance | Maintenance | |
| Infliximab | 0 | 0 | 47.4 | 0 | 0 | 0 | 0 |
| Adalimumab | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Golimumab | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vedolizumab | - | 0 | - | 0 | - | 0 | - |
- Citation: Mei WQ, Hu HZ, Liu Y, Li ZC, Wang WG. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis. World J Gastroenterol 2015; 21(19): 6044-6051
- URL: https://www.wjgnet.com/1007-9327/full/v21/i19/6044.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i19.6044